Patients with myeloproliferative neoplasms (MPN) face a higher mortality risk from COVID-19 infections than the general population, according to a new study. The findings, published in Nature, also show that patients who discontinued ruxolitinib therapy had a ‘striking’ increase in risk of death compared to patients who continued taking the drug. Prior to this, there ...
MPN patients show higher mortality with COVID-19 ‘ruxolitinib discontinuation syndrome’
By Dave Levitan
21 Jan 2021